{"id":390252,"date":"2020-03-30T00:00:00","date_gmt":"2020-03-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0060-2020-biopharma-asthma-treatment-algorithms-claims-data-analysis-pediatric-asthma-us-2020\/"},"modified":"2026-03-31T10:45:29","modified_gmt":"2026-03-31T10:45:29","slug":"algoim0060-2020-biopharma-asthma-treatment-algorithms-claims-data-analysis-pediatric-asthma-us-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0060-2020-biopharma-asthma-treatment-algorithms-claims-data-analysis-pediatric-asthma-us-2020\/","title":{"rendered":"Asthma | Treatment Algorithms: Claims Data Analysis | Pediatric Asthma | US | 2020"},"content":{"rendered":"<p>Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA) and maintenance therapy to prevent exacerbations by targeting underlying pathophysiology (e.g., a LABA\/ICS, such as GSK\u2019s Advair or AstraZeneca\u2019s Symbicort); most pediatric asthma patients receive more than one agent to treat their condition. Despite the availability of multiple, well-established therapies, the pediatric asthma treatment landscape has seen the approval and launch of additional agents in recent years, including salmeterol \/ fluticasone generics and novel biological drugs (e.g., Regeneron \/ Sanofi\u2019s Dupixent, GSK\u2019s Nucala). These events have added more treatment options and fueled competition in this market.<\/p>\n<p><strong>QUESTIONS ANSWERED <\/strong><\/p>\n<ul>\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric asthma patients?<\/li>\n<li>What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric asthma patients?<\/li>\n<li>\u00a0How have newer biological therapies, such as AstraZeneca\u2019s Fasenra, been integrated into the treatment algorithm, and what are their sources of business?<\/li>\n<li>\u00a0What percentage of pediatric asthma patients receive drug therapy within 365 days of diagnosis, and how quickly?<\/li>\n<li>What percentage of patients progress to later lines of therapy within 365 days of diagnosis?<\/li>\n<li>What percentage of pediatric asthma patients are treated with monotherapy versus\u00a0combination therapy?<\/li>\n<li>What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>Geographies<\/strong><\/p>\n<ul>\n<li>United States<\/li>\n<\/ul>\n<p><strong>Real world data<\/strong><\/p>\n<ul>\n<li>\u00a0Longitudinal patient-level claims data analysis<\/li>\n<\/ul>\n<p><strong>Key drugs covered:<\/strong><\/p>\n<ul>\n<li>Advair, Symbicort, Dulera, Breo, Fasenra, Nucala, Xolair, Ventolin, ProAir, montelukast sodium, Flovent, Spiriva<\/li>\n<\/ul>\n<p><strong>Key analysis provided<\/strong><\/p>\n<ul>\n<li>Brand\/therapy usage across longitudinal patient sample<\/li>\n<li>Newly diagnosed patient analysis<\/li>\n<li>Treatment initiation and progression<\/li>\n<li>Line of therapy analysis<\/li>\n<li>Combination therapy analysis<\/li>\n<li>Source of business for recently treated patients<\/li>\n<li>Persistency and compliance analysis<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.<\/p>\n","protected":false},"template":"","class_list":["post-390252","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-asthma","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-942"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390252","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390252\/revisions"}],"predecessor-version":[{"id":393377,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390252\/revisions\/393377"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390252"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}